Autoimmune dermatologic toxicities from immune checkpoint blockade with anti‐PD‐1 antibody therapy: a report on bullous skin eruptions
暂无分享,去创建一个
M. Tetzlaff | P. Nagarajan | G. Jour | D. Ivan | V. Prieto | I. Glitza | P. Aung | J. Curry | R. Rapini | C. Torres-Cabala | A. Huen | C. Drucker | A. Patel | Rachel Ellis | Janet Y. Li | C. Torres‐Cabala
[1] Stanley J. Miller,et al. Skin biopsy: Biopsy issues in specific diseases. , 2016, Journal of the American Academy of Dermatology.
[2] N. Meyer,et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. , 2015, Melanoma research.
[3] A. Daud,et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. , 2015, JAMA dermatology.
[4] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[5] H. Elhalawani,et al. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. , 2015, Future oncology.
[6] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[7] P. Fernández-Peñas,et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. , 2015, Melanoma research.
[8] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[9] A. Goldhirsch,et al. Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander” , 2014, Toxins.
[10] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[11] R. Wolf,et al. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. , 2013, Clinics in dermatology.
[12] K. Yancey,et al. Direct immunofluorescence microscopy of 1 mol/L sodium chloride-treated patient skin. , 1991, Journal of the American Academy of Dermatology.
[13] N. Penneys,et al. Location of basement membrane Type IV collagen beneath subepidermal bullous diseases , 1990, Journal of cutaneous pathology.